UCB and Aitia target Huntington's disease

15 March 2023

Belgian drugmaker UCB (Euronext: UCB) has teamed up with US firm Aitia in an early drug discovery collaboration focused on the discovery and validation of new drug targets and candidates for Huntington’s disease.

Aitia calls itself the leader in the application of causal AI and digital twins, virtual models designed to accurately reflect physical objects, to discover the next generation of breakthrough drugs. Its partners include seven of the top 10 pharmaceutical companies.

The collaboration with UCB seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington’s disease, a debilitating genetic disorder that affects the brain, causing gradual degeneration of nerve cells in specific areas of the brain, which can lead to problems with movement, behavior and cognitive abilities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK